Olipharma, Co. 苏州欧利生物

Suzhou Olipharma was established in 2021. Focusing on Nucleic Acid, we could provide global pharmaceutical companies with "one-stop" nucleic acid CDMO services such as Nucleic Acid Drug Discovery, Laboratory Research and Development, Process and Analysis development, CMC services, Raw Material Drug Production, and Drug Registration. 2021CMC“”CDMO Olipharma has embarked on a global layout, with Compliant, High-Quality, Reliable & Efficient Service to help clients Shorten R&D cycles, Reduce trial costs, Accelerate product Registration and Launch. Assist the entire process of nucleic acid drugs from preclinical to commercial production, and ultimately achieve the corporate vision of "Enabling nucleic acid drugs benefit the world". “”